Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L. reuteri Probiotics vs Antibiotics in Smoker Periodontitis
NCT04209777Phase 3Completed
- Sponsor
- Dow University of Health Sciences
- Start
- Jul 2018
- Primary completion
- Apr 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lactobacillus reuteri in chronic periodontitis (2 arms), sponsored by Dow University of Health Sciences. Primary endpoints: Probing Pocket Depth at 3 months, Clinical Attachment Level at 3 months and 1 more. Started Jul 2018; status: completed.
02
Drugs
lactobacillus reuteri
03
Conditions
chronic periodontitis
Beyond the preview
Go deeper on NCT04209777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209777.